Antithrombotics in acute coronary syndromes: Updates from the past year

Current Treatment Options in Cardiovascular Medicine

Volumn 12, Issue 1, 2010, Pages 84-99

  Bonaca, Marc ^a   Giugliano, Robert P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CANGRELOR; CLOPIDOGREL; DABIGATRAN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; OMEPRAZOLE; OTAMIXABAN; PANTOPRAZOLE; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; RIVAROXABAN; THROMBIN INHIBITOR; TICAGRELOR;

ACUTE CORONARY SYNDROME; BLEEDING; BRAIN HEMORRHAGE; CATHETER THROMBOSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; RECURRENT DISEASE; REVIEW; STENT THROMBOSIS; STROKE; TREATMENT OUTCOME;

EID: 77649192565     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0059-8     Document Type: Review

References (36)

1. World Health Organization: Atlas of Heart Disease and Stroke. Geneva: World Health Organization; 2004.
2. World Health Organization: Global Burden of Disease Study. Geneva: World Health Organization; 2004.
3. Anderson JL, Adams CD, Antman EM, et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007, 50(7):e1-e157. This is an important ACC/AHA guideline for the care of patients with NSTE-ACS.
4. Antman EM, Hand M, Armstrong PW, et al.: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008, 117(2):296-329.
5. Kushner FG, Hand M, Smith SC Jr, et al.; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 120(22):2271-2306.This important ACC/AHA guideline update integrates new evidence regarding the use and timing of antiplatelet agents such as GPIs, clopidogrel, and prasugrel in addition to anticoagulants such as bivalirudin.
6. C Patrono F Bachmann C Baigent, et al. 2004 Expert consensus document on the use of antiplatelet agents. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology Eur Heart J 25 2 166 181 10.1016/j.ehj.2003.10.013 14720534 (Pubitemid 38112156)
7. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology JP Bassand CW Hamm D Ardissino, et al. 2007 Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 13 1598 1660 10.1093/eurheartj/ehm161 1:CAS:528:DC%2BD2sXpslKmtLw%3D 17569677 (Pubitemid 47227122)
8. F Van de Werf J Bax A Betriu, et al. 2008 Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 23 2909 2945 10.1093/eurheartj/ehn416 19004841
9. G Davi C Patrono 2007 Platelet activation and atherothrombosis N Engl J Med 357 24 2482 2494 10.1056/NEJMra071014 1:CAS:528:DC%2BD2sXhsVemurrL 18077812 (Pubitemid 350272787)
10. S Kulkarni SM Dopheide CL Yap, et al. 2000 A revised model of platelet aggregation J Clin Invest 105 6 783 791 10.1172/JCI7569 1:CAS:528: DC%2BD3cXhvFehsbo%3D 10727447
11. Mehta SR: CURRENT OASIS 7: A 2∈×∈2 factorial randomized trial of optimal clopidogrel and aspirin dosing in patients with ACS undergoing an early invasive strategy with intent for PCI. Proceedings of the European Society of Cardiology 2009 Congress. Barcelona, Spain; August 30-September 2, 2009.
12. SR Mehta CB Granger JW Eikelboom, et al. 2007 Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial J Am Coll Cardiol 50 18 1742 1751 10.1016/j.jacc.2007.07.042 1:CAS:528: DC%2BD2sXht1aktL3O 17964037 (Pubitemid 47600591)
13. S Yusuf F Zhao SR Mehta, et al. 2001 Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 7 494 502 10.1056/NEJMoa010746 1:CAS:528: DC%2BD3MXms1arsrY%3D 11519503 (Pubitemid 32758501)
14. SR Mehta S Yusuf RJ Peters, et al. 2001 Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 9281 527 533 10.1016/S0140-6736(01)05701-4 1:CAS:528:DC%2BD3MXmtV2ht7g%3D 11520521 (Pubitemid 32772726)
15. JL Mega SL Close SD Wiviott, et al. 2009 Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 4 354 362 10.1056/NEJMoa0809171 1:CAS:528:DC%2BD1MXhtVSlsbs%3D 19106084 Mega et al. identify a common genetic polymorphism associated with altered clopidogrel metabolism and adverse outcomes.
16. PM Ho TM Maddox L Wang, et al. 2009 Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 9 937 944 10.1001/jama.2009.261 1:CAS:528: DC%2BD1MXivFejt7g%3D 19258584
17. T Cuisset C Frere J Quilici, et al. 2009 Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study J Am Coll Cardiol 54 13 1149 1153 10.1016/j.jacc.2009.05.050 1:CAS:528:DC%2BD1MXht1GntbbK 19761935
18. ML O'Donoghue E Braunwald EM Antman, et al. 2009 Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 9694 989 997 10.1016/S0140-6736(09)61525-7 19726078
19. Bhatt DL: The COGENT trial. Proceedings of the Transcatheter Cardiovascular Therapeutics Conference. San Francisco, CA: September 24, 2009.
20. US Food and Drug Administration: Clopidogrel (marketed as Plavix) and omeprazole (marketed as Prilosec)-drug interaction. Available at < http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm190848.htm >. Accessed December 2009.
21. SD Wiviott E Braunwald CH McCabe, et al. 2007 Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 20 2001 2015 10.1056/NEJMoa0706482 1:CAS:528:DC%2BD2sXhtlWis7rN 17982182 As this article demonstrates, TRITON-TIMI 38 showed a reduction in adverse ischemic outcomes with a more potent platelet inhibitor, prasugrel. There was an especially strong benefit in high-risk subgroups, such as diabetic patients. However, there also was an associated increased risk of bleeding overall, particularly in subgroups with a history of stroke. These findings underscore the importance of careful patient selection in choosing antithrombotic therapy. (Pubitemid 350106708)
22. G Montalescot SD Wiviott E Braunwald, et al. 2009 Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 9665 723 731 10.1016/S0140-6736(09)60441-4 1:CAS:528:DC%2BD1MXisVOrsbc%3D 19249633
23. JL Mega SL Close SD Wiviott, et al. 2009 Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 19 2553 2560 10.1161/CIRCULATIONAHA.109.851949 1:CAS:528:DC%2BD1MXmtVKntrs%3D 19414633
24. RP Giugliano JA White C Bode, et al. 2009 Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 21 2176 2190 10.1056/NEJMoa0901316 1:CAS:528:DC%2BD1MXmsVSksrY%3D 19332455 This study helped evaluate the strategy of routine upfront use of GPIs compared with provisional use during PCI. The findings are important for therapeutic decision making.
25. L Wallentin RC Becker A Budaj, et al. 2009 Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 11 1045 1057 10.1056/NEJMoa0904327 1:CAS:528:DC%2BD1MXhtFaltL%2FJ 19717846
26. DL Bhatt AM Lincoff CM Gibson, et al. 2009 Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 24 2330 2341 10.1056/NEJMoa0908629 1:CAS:528:DC%2BD1MXhsFGltr7P 19915222
27. RA Harrington GW Stone S McNulty, et al. 2009 Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 24 2318 2329 10.1056/NEJMoa0908628 1:CAS:528:DC%2BD1MXhsFGlsbfF 19915221
28. GW Stone BT McLaurin DA Cox, et al. 2006 Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 21 2203 2216 10.1056/NEJMoa062437 1:CAS:528:DC%2BD28Xht1Chsb3L 17124018 (Pubitemid 44791162)
29. GW Stone B Witzenbichler G Guagliumi, et al. 2008 Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 21 2218 2230 10.1056/NEJMoa0708191 1:CAS:528:DC%2BD1cXmt1Gju7Y%3D 18499566 This trial evaluated bivalirudin in acute myocardial infarction. (Pubitemid 351724451)
30. R Mehran AJ Lansky B Witzenbichler, et al. 2009 Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 9696 1149 1159 10.1016/S0140-6736(09)61484-7 19717185
31. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators S Yusuf SR Mehta S Chrolavicius, et al. 2006 Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 14 1464 1476 10.1056/NEJMoa055443 1:CAS:528:DC%2BD28XjtFWhuro%3D 16537663
32. S Yusuf SR Mehta S Chrolavicius, et al. 2006 Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 295 13 1519 1530 10.1001/jama.295.13.joc60038 1:CAS:528:DC%2BD28Xjt12isbs%3D 16537725
33. MS Sabatine EM Antman P Widimsky, et al. 2009 Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Lancet 374 9692 787 795 10.1016/S0140-6736(09)61454-9 1:CAS:528:DC%2BD1MXhtV2ksLnK 19717184
34. JL Mega E Braunwald S Mohanavelu, et al. 2009 Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 9683 29 38 10.1016/S0140-6736(09)60738-8 1:CAS:528:DC%2BD1MXotFCgtLc%3D 19539361
35. APPRAISE Steering Committee and Investigators JH Alexander RC Becker DL Bhatt, et al. 2009 Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 22 2877 2885 10.1161/CIRCULATIONAHA.108.832139 19470889
36. Oldgren J: Randomised dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel: RE-DEEM. Proceedings of the American Heart Association Scientific Sessions 2009. Orlando, FL; November 14-18, 2009.